Customer Case Study

Regeneron is a leading biotechnology company using the power of science to bring new medicines to patients in need.

Vertical Use Case

  • Genomic and clinical data is highly decentralized, making it very difficult to analyze and train models against the entire dataset

Technical Use Case

  • Data Ingest and ETL
  • Machine Learning

The Challenges

More than 95% of all  experimental medicines that are currently in the drug development pipeline are expected to fail. To improve these efforts, the Regeneron Genetics Center built one of the most comprehensive genetics databases by pairing the sequenced exomes and electronic health records of more than 400,000 people. However, they faced numerous challenges analyzing this massive set of data:

  • Genomic and clinical data is highly decentralized, making it very difficult to analyze and train models against their entire 10TB dataset
  • Difficult and costly to scale their legacy architecture to support analytics on over 80 billion data points
  • Data teams were spending days just trying to ETL the data so that it can be used for analytics

The Solution

Databricks provides Regeneron with a unified analytics platform running on Amazon Web Services that simplifies operations and accelerates drug discovery through improved data science productivity. This is empowering them to analyze the data in new ways that were previously impossible.

  • Automated cluster management: simplifies the provisioning of clusters, reducing time spent on DevOps work so engineers and data scientists can spend more time on high valued tasks
  • Interactive workspaces: allows data scientists to share data and insights, fostering an environment of transparency and collaboration across the entire drug development lifecycle
  • Performant Spark-powered Pipelines: significantly improved reliability and speed of ETL pipelines used to process their 10TBs of EHR  + DNAseq data

With Databricks we have been able to reduce the time it takes to ETL massive amounts of data from weeks to just a few hours to greatly accelerate drug discovery.

Lukas Habegger, Associate Director of Bioinformatics at the Regeneron Genetics Center

The Results

  • Accelerated Drug Target Identification: reduced the time it takes data scientists and computational biologists to run queries on their entire dataset from 30 minutes to down 3 seconds – 600x improvement!
  • Increased Productivity: improved collaboration, automated DevOps and accelerated pipelines (ETL in 2 days vs 3 weeks) have enabled their teams to support a broader range of studies

“The Databricks Unified Analytics Platform is enabling everyone in our integrated drug development process – from physician-scientists to computational biologists – to easily access, analyze, and extract insights from all of our data”

-Jeffrey Reid, PhD, Head of Genome Informatics at Regeneron